Canopus BioPharma Incorporated (CBIA)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2014 | 2013 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | 9873.00 | 9873.00 |
| Gross Profit | - | - | -9873.00 | -9873.00 |
| Operating Expenses | 764.56 Thousand | 1755.00 | 500.3 Thousand | 108.55 Thousand |
| Selling, General and Administrative Expenses | 764.56 Thousand | 1755.00 | 86.69 Thousand | 66.55 Thousand |
| Research and Development Expenses | - | - | 413.61 Thousand | 42 Thousand |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 764.56 Thousand | 1755.00 | 510.17 Thousand | 118.42 Thousand |
| Operating Income | -764.56 Thousand | -1760.00 | -510.17 Thousand | -118.43 Thousand |
| Interest Expense | 145.00 | - | 385.63 Thousand | 393.12 Thousand |
| Income Tax Expense | -228.48 Thousand | -236.55 Thousand | 1.00 | -8.00 |
| Earnings before Tax | -764.7 Thousand | -1755.00 | -850.93 Thousand | -525.93 Thousand |
| Net Income | -764.7 Thousand | -1755.00 | -850.93 Thousand | -525.93 Thousand |
| Earnings Per Share Basic | -0.01 | - | -0.02 | -0.02 |
| Earnings Per Share Diluted | -0.01 | - | -0.02 | -0.02 |
| Weighted Average Shares Outstanding | 109.62 Million | 98.24 Million | 40.71 Million | 21.09 Million |
| Weighted Average Shares Outstanding (Diluted) | 109.62 Million | 98.24 Million | 40.71 Million | 21.09 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -764.56 Thousand | -1760.00 | -108.56 Thousand | -108.56 Thousand |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 190.45 Thousand | 782.54 Thousand | 3718.00 | 425.08 Thousand | 764.56 Thousand |
| Selling, General and Administrative Expenses | - | 190.45 Thousand | 782.54 Thousand | 3718.00 | 425.08 Thousand | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | - | 190.45 Thousand | 782.54 Thousand | 3718.00 | 425.08 Thousand | 764.56 Thousand |
| Operating Income | - | -190.46 Thousand | -782.55 Thousand | -3720.00 | -425.08 Thousand | -764.56 Thousand |
| Interest Expense | - | 13.48 Thousand | 125.00 | 125.00 | - | 145.00 |
| Income Tax Expense | - | -122.08 Thousand | -41.58 Thousand | -54.88 Thousand | -27.08 Thousand | -228.48 Thousand |
| Earnings before Tax | - | -203.94 Thousand | -782.67 Thousand | -3718.00 | -425.22 Thousand | -764.7 Thousand |
| Net Income | - | -203.94 Thousand | -782.67 Thousand | -3718.00 | -425.22 Thousand | -764.7 Thousand |
| Earnings Per Share Basic | - | -0.00 | -0.01 | - | -0.00 | - |
| Earnings Per Share Diluted | - | -0.00 | -0.01 | - | -0.00 | - |
| Weighted Average Shares Outstanding | - | 139.89 Million | 126.44 Million | 122.09 Million | 123.72 Million | 109.62 Million |
| Weighted Average Shares Outstanding (Diluted) | - | 139.89 Million | 126.44 Million | 122.09 Million | 123.72 Million | 109.62 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | -190.46 Thousand | -782.55 Thousand | -3720.00 | -425.08 Thousand | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
DBGI
SLNG
2515
FRX
ADVLIFE
180640